Local view for "http://purl.org/linkedpolitics/eu/plenary/2007-07-12-Speech-4-192"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20070712.23.4-192"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
".
The pairing of ‘Medicines and poor countries of the South’ poses a problem in terms of the reconciling of ‘Intellectual property law of pharmaceutical laboratories and human rights to health care’.
In Hong Kong, the WTO summit reached an agreement, the results of which have yet to be felt in the areas of tuberculosis, malaria and AIDS. Medicines, whether generic or not, are not accessible to the people.
However, the substance of this audacious solution presupposes that the ‘common heritage of mankind’ concept, dating back to the 1960s, has been taken up here.
Major diseases are spread worldwide by people migrating and travelling. These diseases can strike down mankind. We saw this with SARS and avian influenza. Therefore, for worldwide diseases, we need worldwide medicines.
Medicines that are used to treat worldwide diseases must have a ‘common heritage of mankind patent’.
The legal status of these 21st century patents would be open, as would the tax to be paid from intergovernmental contributions. Thought may be given to ‘public-private partnerships’ involving ‘multinational pharmaceutical companies and the WHO’ or governments. Thought may be also given to a ‘Company’ with international status, of the type stipulated for sea bed exploitation.
The important thing is the innovative principle of the worldwide management of the risks of worldwide pandemics."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples